Evidence for cross-protection but not type-replacement over the 11 years after human papillomavirus vaccine introduction

References

• Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108. doi:10.3322/caac.21262.
   PubMed Web of Science ®Google Scholar
• Chaturvedi AK. Beyond cervical cancer: burden of other HPV-related cancers among men and women. J Adolesc Health. 2010;46(4 Suppl):S20–6. doi:10.1016/j.jadohealth.2010.01.016.
   PubMed Web of Science ®Google Scholar
• Gillison ML, Chaturvedi AK, Lowy DR. HPV prophylactic vaccines and the potential prevention of noncervical cancers in both men and women. Cancer. 2008;113(10 Suppl):3036–46. doi:10.1002/cncr.23764.
   PubMed Web of Science ®Google Scholar
• Parkin DM, Bray F. Chapter 2: the burden of HPV-related cancers. Vaccine. 2006;24(Suppl 3):S11–25. doi:10.1016/j.vaccine.2006.05.111.
   Web of Science ®Google Scholar
• Petrosky E, Bocchini JA, Hariri S, Chesson H, Curtis CR, Saraiya M, Unger ER, Markowitz LE. Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the advisory committee on immunization practices. MMWR Morb Mortal Wkly Rep. 2015;64:300–04.
   PubMed Web of Science ®Google Scholar
• Li N, Franceschi S, Howell-Jones R, Snijders PJF, Clifford GM. Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: variation by geographical region, histological type and year of publication. Int J Cancer. 2011;128(4):927–35. doi:10.1002/ijc.25396.
   PubMed Web of Science ®Google Scholar
• Spinner C, Ding L, Bernstein DI, Brown DR, Franco EL, Covert C, Kahn JA. Human papillomavirus vaccine effectiveness and herd protection in young women: 2006–2017. Pediatrics. 2019; e20181902. doi: 10.1542/peds.2018-1902.
   Web of Science ®Google Scholar
• Brown DR, Kjaer SK, Sigurdsson K, Iversen O-E, Hernandez-Avila M, Wheeler CM, Perez G, Koutsky LA, Tay EH, Garcia P, et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16–26 years. J Infect Dis. 2009;199(7):926–35. doi:10.1086/597307.
   PubMed Web of Science ®Google Scholar
• Malagon T, Drolet M, Boily M-C, Franco EL, Jit M, Brisson J, Brisson M. Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis. Lancet Infect Dis. 2012;12(10):781–89. doi:10.1016/S1473-3099(12)70187-1.
   PubMed Web of Science ®Google Scholar
• Paavonen J, Naud P, Salmerón J, Wheeler CM, Chow S-N, Apter D, Kitchener H, Castellsague X, Teixeira JC, Skinner SR, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet. 2009;374(9686):301–14. doi:10.1016/S0140-6736(09)61248-4.
   PubMed Web of Science ®Google Scholar
• Safaeian M, Rodriguez AC. Invited commentary: multiple human papillomavirus infections and type replacement-anticipating the future after human papillomavirus vaccination. Am J Epidemiol. 2014;180(11):1076–81. doi:10.1093/aje/kwu265.
   PubMed Web of Science ®Google Scholar
• Cornall AM, Phillips S, Cummins E, Garland SM, Tabrizi SN. In vitro assessment of the effect of vaccine-targeted human papillomavirus (HPV) depletion on detection of non-vaccine HPV types: implications for post-vaccine surveillance studies. J Virol Methods. 2015;214:10–14. doi:10.1016/j.jviromet.2014.12.007.
   PubMed Web of Science ®Google Scholar
• Stanley M, Lowy DR, Frazer I. Chapter 12: prophylactic HPV vaccines: underlying mechanisms. Vaccine. 2006;24(Suppl 3):S106–13. doi:10.1016/j.vaccine.2006.05.110.
   Web of Science ®Google Scholar
• Bernard HU. Coevolution of papillomaviruses with human populations. Trends Microbiol. 1994;2:140–43.
   PubMedGoogle Scholar
• Adam HJ, Richardson SE, Jamieson FB, Rawte P, Low DE, Fisman DN. Changing epidemiology of invasive haemophilus influenzae in Ontario, Canada: evidence for herd effects and strain replacement due to Hib vaccination. Vaccine. 2010;28(24):4073–78. doi:10.1016/j.vaccine.2010.03.075.
   PubMed Web of Science ®Google Scholar
• Kaur R, Casey JR, Pichichero ME. Emerging streptococcus pneumoniae strains colonizing the nasopharynx in children after 13-valent pneumococcal conjugate vaccination in comparison to the 7-valent Era, 2006–2015. Pediatr Infect Dis J. 2016;35(8):901–06. doi:10.1097/INF.0000000000001206.
   PubMed Web of Science ®Google Scholar
• Singleton RJ, Hennessy TW, Bulkow LR, Hammitt LL, Zulz T, Hurlburt DA, Butler JC, Rudolph K, Parkinson A. Invasive pneumococcal disease caused by nonvaccine serotypes among alaska native children with high levels of 7-valent pneumococcal conjugate vaccine coverage. Jama. 2007;297(16):1784–92. doi:10.1001/jama.297.16.1784.
   PubMed Web of Science ®Google Scholar
• Gray P, Palmroth J, Luostarinen T, Apter D, Dubin G, Garnett G, Eriksson T, Natunen K, Merikukka M, Pimenoff V, et al. Evaluation of HPV type-replacement in unvaccinated and vaccinated adolescent females-Post-hoc analysis of a community-randomized clinical trial (II). Int J Cancer. 2018;142(12):2491–500. doi:10.1002/ijc.31281.
   PubMed Web of Science ®Google Scholar
• Merikukka M, Kaasila M, Namujju PB, Palmroth J, Kirnbauer R, Paavonen J, Surcel H-M, Lehtinen M. Differences in incidence and co-occurrence of vaccine and nonvaccine human papillomavirus types in Finnish population before human papillomavirus mass vaccination suggest competitive advantage for HPV33. Int J Cancer. 2011;128(5):1114–19. doi:10.1002/ijc.25675.
   PubMed Web of Science ®Google Scholar
• Mesher D, Soldan K, Lehtinen M, Beddows S, Brisson M, Brotherton JML, Chow EPF, Cummings T, Drolet M, Fairley CK, et al. Population-level effects of human papillomavirus vaccination programs on infections with nonvaccine genotypes. Emerg Infect Dis. 2016;22(10):1732–40. doi:10.3201/eid2210.160675.
   PubMed Web of Science ®Google Scholar
• Yang Z, Cuzick J, Hunt WC, Wheeler CM. Concurrence of multiple human papillomavirus infections in a large US population-based cohort. Am J Epidemiol. 2014;180(11):1066–75. doi:10.1093/aje/kwu267.
   PubMed Web of Science ®Google Scholar
• Saccucci M, Franco EL, Ding L, Bernstein DI, Brown D, Kahn JA. Non-vaccine-type human papillomavirus prevalence after vaccine introduction: no evidence for type replacement but evidence for cross-protection. Sex Transm Dis. 2018;45(4):260–65. doi:10.1097/OLQ.0000000000000731.
   PubMed Web of Science ®Google Scholar
• Drolet M, Bénard É, Boily M-C, Ali H, Baandrup L, Bauer H, Beddows S, Brisson J, Brotherton JML, Cummings T, et al. Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infect Dis. 2015;15(5):565–80. doi:10.1016/S1473-3099(14)71073-4.
   PubMed Web of Science ®Google Scholar
• Draper E, Bissett SL, Howell-Jones R, Edwards D, Munslow G, Soldan K, Beddows S. Neutralization of non-vaccine human papillomavirus pseudoviruses from the A7 and A9 species groups by bivalent HPV vaccine sera. Vaccine. 2011;29(47):8585–90. doi:10.1016/j.vaccine.2011.09.021.
   PubMed Web of Science ®Google Scholar
• Carozzi F, Puliti D, Ocello C, Anastasio PS, Moliterni EA, Perinetti E, Serradell L, Burroni E, Confortini M, Matellini P, et al. Monitoring vaccine and non-vaccine HPV type prevalence in the post-vaccination era in women living in the Basilicata region, Italy. BMC Infect Dis. 2018;18(1):38. doi is: 10.1186/s12879-018-2945-8.
   PubMed Web of Science ®Google Scholar
• Tota JE, Ramanakumar AV, Villa LL, Richardson H, Burchell AN, Coutlée F, Franco EL. Cervical infection with vaccine-associated human papillomavirus (HPV) genotypes as a predictor of acquisition and clearance of other HPV infections. J Infect Dis. 2016;214(5):676–84. doi:10.1093/infdis/jiw215.
   PubMed Web of Science ®Google Scholar
• Poljak M, Kocjan BJ, Oštrbenk A, Seme K. Commercially available molecular tests for human papillomaviruses (HPV): 2015 update. J Clin Virol. 2016;76(Suppl 1):S3–s13. doi:10.1016/j.jcv.2015.10.023.
   PubMed Web of Science ®Google Scholar
• Poljak M, Kocjan BJ. Commercially available assays for multiplex detection of alpha human papillomaviruses. Expert Rev Anti Infect Ther. 2010;8(10):1139–62. doi:10.1586/eri.10.104.
   PubMed Web of Science ®Google Scholar
• Thomas R, Higgins L, Ding L, Widdice LE, Chandler E, Kahn JA. Factors associated with hpv vaccine initiation, vaccine completion, and accuracy of self-reported vaccination status among 13- to 26-year-old men. Am J Mens Health. 2018; 12(4):819–827. doi:10.1177/1557988316645155.
   Web of Science ®Google Scholar
• Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res. 2011;46(3):399–424. doi:10.1080/00273171.2011.568786.
   PubMed Web of Science ®Google Scholar
• Imbens GW. The role of the propensity score in estimating dose-response functions. Biometrika. 2000;87:706–10. doi:10.1093/biomet/87.3.706.
   Web of Science ®Google Scholar
• Kahn JA, Brown DR, Ding L, Widdice LE, Shew ML, Glynn S, Bernstein DI. Vaccine-type human papillomavirus and evidence of herd protection after vaccine introduction. Pediatrics. 2012;130(2):e249–56. doi:10.1542/peds.2011-3587.
   PubMed Web of Science ®Google Scholar
• Kahn JA, Widdice LE, Ding L, Huang B, Brown DR, Franco EL, Bernstein DI. Substantial decline in vaccine-type human papillomavirus (HPV) among vaccinated young women during the first 8 years after HPV vaccine introduction in a community. Clin Infect Dis. 2016;63(10):1281–87. doi:10.1093/cid/ciw533.
   PubMed Web of Science ®Google Scholar
• Brookhart MA, Schneeweiss S, Rothman KJ, Glynn RJ, Avorn J, Stürmer T. Variable selection for propensity score models. Am J Epidemiol. 2006;163(12):1149–56. doi:10.1093/aje/kwj149.
   PubMed Web of Science ®Google Scholar